Schiff Assists Biofrontera in $15M Private Placement
Schiff Hardin LLP advised the placement agents for Biofrontera Inc.’s $15 million private placement with a single institutional investor for the purchase of 2,857,143 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 2,857,143 shares of common stock.
Schiff Hardin LLP advised the placement agents for Biofrontera Inc.’s $15 million private placement with a single institutional investor for the purchase of 2,857,143 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 2,857,143 shares of common stock. Biofrontera is a biopharmaceutical company specializing in the commercialization of dermatological products.
Roth Capital Partners and The Benchmark Company acted as the exclusive placement agents for the private offering, which closed Dec. 1, 2021.
Contacts
-
Contact:
Nathan Carlile, Head of Firmwide Communications
- Related Practices